259 related articles for article (PubMed ID: 36705855)
21. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
22. What are the molecular mechanisms driving the switch from MPNs to leukemia?
Wang X; Hoffman R
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
[TBL] [Abstract][Full Text] [Related]
23. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
24. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
25. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
26. JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?
Kucine N; Levine RL
Ther Adv Hematol; 2011 Aug; 2(4):203-11. PubMed ID: 23556090
[TBL] [Abstract][Full Text] [Related]
27. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
28. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
Duminuco A; Vetro C; Giallongo C; Palumbo GA
Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
[TBL] [Abstract][Full Text] [Related]
29. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
30. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
32. New Treatments for Myelofibrosis.
Tremblay D; Mesa R
Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
[TBL] [Abstract][Full Text] [Related]
33. Immunological Consequences of JAK Inhibition: Friend or Foe?
McLornan DP; Khan AA; Harrison CN
Curr Hematol Malig Rep; 2015 Dec; 10(4):370-9. PubMed ID: 26292803
[TBL] [Abstract][Full Text] [Related]
34. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
35. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
36. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
39. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
40. Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.
Cattaneo D; Iurlo A
Front Immunol; 2021; 12():750346. PubMed ID: 34867980
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]